Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Akebia Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On November 28, 2025, we entered into an Asset Purchase Agreement with Akebia Therapeutics, Inc. ("Akebia") pursuant to which we sold to Akebia substantially all of our assets related to the research, development, manufacture and commercialization of ADX-097 (the "ADX-097 Asset Sale").”
FILING10-K0001193125-26-099339cik 0001661998disclosed by QTTB
“We have entered into supply agreements with STA Pharmaceutical Hong Kong Limited, or STA , for the manufacture of Vafseo drug substance and drug product for commercial use and Patheon Inc. for the manufacture of Vafseo drug product for commercial use.”
FILING10-K0001517022-26-000020cik 0001517022
“A uryxia drug product is supplied by Patheon Manufacturing Services LLC (Thermo Fisher) pursuant to a Master Manufacturing Service Agreement with per-bottle pricing structured on a tiered basis, with the price reduced as the product volume increases.”
FILING10-K0001517022-26-000020cik 0001517022
“We have entered into supply agreements with STA Pharmaceutical Hong Kong Limited, or STA , for the manufacture of Vafseo drug substance and drug product for commercial use and Patheon Inc. for the manufacture of Vafseo drug product for commercial use.”
FILING10-K0001517022-26-000020cik 0001517022
“We have also engaged Cardinal Health, Inc., as the exclusive third-party logistics distribution agent for commercial sales of Auryxia and Vafseo.”
FILING10-K0001517022-26-000020cik 0001517022
“On November 28, 2025, or the APA Closing Date , we entered into an Asset Purchase Agreement, or the Q32 Purchase Agreement , with Q32, pursuant to which we purchased and assumed from Q32 substantially all assets and liabilities of Q32 and its affiliates related to the research, development, manufacture and commercialization of Q32's clinical-stage development candidate known as ADX-097, now referred to as AKB-097, worldwide for the treatment, prevention or diagnosis of any disease or condition in humans.”
FILING10-K0001517022-26-000020cik 0001517022
“Most dialysis clinics operate within dialysis organization networks, the largest of which are DaVita, Inc., or DaVita , Fresenius KidneyCare Group LLC, or Fresenius , and U.S. Renal Care, or USRC .”
FILING10-K0001517022-26-000020cik 0001517022
“Most dialysis clinics operate within dialysis organization networks, the largest of which are DaVita, Inc., or DaVita , Fresenius KidneyCare Group LLC, or Fresenius , and U.S. Renal Care, or USRC .”
FILING10-K0001517022-26-000020cik 0001517022
“In September 2007, we entered into a Sublicense Agreement with JT and Torii, under which JT and Torii obtained the exclusive sublicense rights for the development and commercialization of ferric citrate in Japan.”
FILING10-K0001517022-26-000020cik 0001517022
“In December 2015, we entered into a collaboration agreement with Tanabe Pharma Corporation, or TPC , formerly known as Mitsubishi Tanabe Pharma Corporation, as amended, or the TPC Agreement , providing TPC with exclusive development and commercialization rights to Vafseo in Japan and certain other Asian countries, or the TPC Territory .”
FILING10-K0001517022-26-000020cik 0001517022
“Most dialysis clinics operate within dialysis organization networks, the largest of which are DaVita, Inc., or DaVita , Fresenius KidneyCare Group LLC, or Fresenius , and U.S. Renal Care, or USRC .”
FILING10-K0001517022-26-000020cik 0001517022
“Akebia may not be successful in developing and commercializing any therapies through its praliciguat out-license with the Company.”
FILING10-K0001193125-26-132193cik 0001755237disclosed by CYCN
“On December 22, 2022, we and Averoa entered into a license agreement, or Averoa License Agreement , pursuant to which we granted to Averoa an exclusive license to develop and commercialize ferric citrate, or Averoa Licensed Product, in the EEA, Turkey, Switzerland and the United Kingdom, and in August 2024, we also granted Averoa an exclusive license to develop and commercialize ferric citrate in the Balkans and certain countries in Eastern Europe and the Middle East, or collectively, the Averoa Territory .”
FILING10-K0001517022-26-000020cik 0001517022
“Together with Dialysis Clinic, Inc. or DCI , and Innovative Renal Care, or IRC , these top five U.S. dialysis organizations treat 82% of the total dialysis patient population.”
FILING10-K0001517022-26-000020cik 0001517022
“Together with Dialysis Clinic, Inc. or DCI , and Innovative Renal Care, or IRC , these top five U.S. dialysis organizations treat 82% of the total dialysis patient population.”
FILING10-K0001517022-26-000020cik 0001517022
“On May 24, 2023, or the Medice Effective Date , we entered into a License Agreement, or the Medice License Agreement , with Medice, under which we granted to Medice an exclusive license to develop and commercialize Vafseo for the treatment of anemia in adult patients with chronic kidney disease in the European Economic Area, or EEA , UK, Switzerland and Australia, or the Medice Territory .”
FILING10-K0001517022-26-000020cik 0001517022
“On February 5, 2025, we entered into an Authorized Generic Distribution and Supply Agreement with Mylan Pharmaceuticals, Inc., as amended in September 2025, pursuant to which, they are currently selling an authorized generic version of Auryxia.”
FILING10-K0001517022-26-000020cik 0001517022
“In September 2007, we entered into a Sublicense Agreement with JT and Torii, under which JT and Torii obtained the exclusive sublicense rights for the development and commercialization of ferric citrate in Japan.”
FILING10-K0001517022-26-000020cik 0001517022
“The Panion Amended License Agreement provides us with an exclusive license under Panion-owned know-how and patents covering the rights to sublicense, develop, make, use, sell, offer for sale, import and export ferric citrate worldwide, excluding certain Asian Pacific countries, or the Licensor Territory .”
FILING10-K0001517022-26-000020cik 0001517022
“On February 18, 2022, we entered into a Second Amended and Restated License Agreement, or the Vifor License Agreement , with Vifor (International) Ltd. (now a part of CSL Limited), or CSL Vifor , which amended and restated the License Agreement dated as of May 12, 2017.”
FILING10-K0001517022-26-000020cik 0001517022
“In February 2021, we entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or HCR , whereby we sold our right to receive royalties and sales milestones for Vafseo in Japan and certain other Asian countries in the TPC territory under the TPC Agreement, subject to certain caps and other terms and conditions.”
FILING10-K0001517022-26-000020cik 0001517022
Watchlist prices, news filtered to it, and its next report on your desk.
Akebia Therapeutics, Inc. has 8 disclosed suppliers and 13 disclosed customers. Each one is named in an SEC filing, either Akebia Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
AKBA (Akebia Therapeutics, Inc.) has 8 disclosed suppliers and 13 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.